Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.

Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.

Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.

Bears Say

Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.

Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.

Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

10.56% Insiders

6.66% Mutual Funds

0.16% Other Institutional Investors

76.31% Public Companies and Individual Investors

Detailed Ownership Overview >

VERU FAQ

What was Veru’s price range in the past 12 months?

Veru lowest stock price was $0.45 and its highest was $1.42 in the past 12 months.

What is Veru’s market cap?

Veru’s market cap is $87.94M.

When is Veru’s upcoming earnings report date?

Veru’s upcoming earnings report date is Aug 07, 2025 which is in 19 days.

How were Veru’s earnings last quarter?

Veru released its earnings results on May 08, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.012.

Is Veru overvalued?

According to Wall Street analysts Veru’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Veru pay dividends?

Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here

What is Veru’s EPS estimate?

Veru’s EPS estimate is -0.05.

How many shares outstanding does Veru have?

Veru has 146,583,920 shares outstanding.

What happened to Veru’s price movement after its last earnings report?

Veru reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went up 4%.

Which hedge fund is a major shareholder of Veru?

Currently, no hedge funds are holding shares in VERU

Veru Stock Smart Score

Underperform

Fundamentals

Return on Equity

-88.03%

Trailing 12-Months

Asset Growth

-54.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Veru

Veru Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel medicines for the management of prostate cancer and other cancers. The company is also involved in the development of pharmaceuticals for the prevention of COVID-19. Veru operates primarily in the United States and its core products and services include oncology drug candidates and pharmaceutical products in the sexual health sector.

VERU Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented several positive developments, such as successful Phase 2b study results for enobosarm and financial improvements in net loss from continuing operations. However, the company faces challenges with increased R&D costs, a significant decrease in cash reserves, and a net loss on the sale of the FC2 business. While there are promising regulatory and clinical catalysts ahead, the need for additional funding is a concern.Read More>